兴齐眼药(300573.SZ)：SQ-22031滴眼液治疗中至重度干眼Ⅱ期临床试验首例受试者入组

Core Viewpoint - The company has initiated the Phase II clinical trial for its SQ-22031 eye drops, aimed at treating moderate to severe dry eye syndrome, marking a significant step in its research and development efforts [1] Group 1: Clinical Trial Details - The SQ-22031 eye drops have completed the enrollment of the first subject in a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study [1] - The primary objective of the Phase II study is to evaluate the efficacy and safety of SQ-22031 eye drops in patients with moderate to severe dry eye [1] - The study will also analyze the immunogenicity of the product and its impact on corneal nerve density changes [1]